<DOC>
	<DOCNO>NCT01336166</DOCNO>
	<brief_summary>The aim study investigate long-term immunogenicity safety inactivate split-virion vaccine one immunization .</brief_summary>
	<brief_title>The Long-term Immunogenicity Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Different age group 18 60 year , normal intelligence health . Volunteers ( guardian ) well inform situation sign consent 2 . Vaccination recipient qualify product inquired medical history clinically proven healthy 3 . Requests clinical research program obey 4 . No protective product inoculate last week 5 . Axillary temperature 37 degree Celsius 1 . Volunteers another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination 2 . Volunteers allergic ingredient vaccine composition ( checked vaccination history ) , especially egg 3 . History progressive severe neurologic disorder 4 . Serious adverse reaction vaccine anaphylaxis , hive , respiratory difficulty , angioedema , abdominal pain 5 . Known suspected impairment/alteration immune function , example receive immunosuppressive therapy receive blood , blood product and/or plasma derivative parenteral immunoglobulin preparation 6 . Asthma unstable require emergent care , hospitalization intubation past two year require use oral intravenous corticosteroid 7 . Bleeding disorder diagnose doctor ( e.g . factor deficiency , coagulopathy , platelet disorder require special precaution ) significant bruise bleed difficulty IM injection blood draws 8 . History thyroidectomy thyroid disease require medication within past 12 month 9 . Serious angioedema episode within previous 3 year require medication previous two year 10 . GuillainBarre Syndrome 11 . Selfreported seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C 12 . Any vaccine immunoglobulin preparation within 1 week prior enrollment 13 . Axillary temperature â‰¥ 38.0 degree Celsius within 3 day intend study vaccination 14 . Any condition may influence evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>H1N1</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
</DOC>